Several biotech and therapeutics companies posted notable gains in after-hours trading on Tuesday, December 2, 2025, following a mix of corporate updates, investor anticipation, and recent scientific disclosures.
Clene Inc. (CLNN) shares surged in after-hours trading, climbing 8.53% to $10.05 after closing the regular session down 3.14% at $9.26. The late clinical-stage biopharmaceutical company, along with its subsidiary Clene Nanomedicine, announced plans to provide an update on its CNM-Au8 program in amyotrophic lateral sclerosis (ALS). The company will host an investor call and webcast at 8:30 a.m. ET on December 3, 2025, fueling investor optimism ahead of the event.
Werewolf Therapeutics, Inc. (HOWL) advanced 6.12% after hours to $0.91, recovering from a 6.20% decline at the close to $0.86. While no fresh news was released Tuesday, investors may still be digesting the company's November 7 presentation at the Society for Immunotherapy of Cancer's Annual Meeting, where it highlighted novel strategies from its proprietary PREDATOR platform. The company also reported a Q3 net loss of $16.4 million earlier in November, slightly narrower than the prior year.
Biomea Fusion, Inc. (BMEA) gained 7.31% in after-hours trading, reaching $1.03 after closing at $0.96, down 5.22%. On December 1, the company announced its selection for an oral presentation of long-term icovamenib follow-up data at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease. The upcoming presentation in Los Angeles is expected to showcase advancements in metabolic disease research.
Denali Therapeutics Inc. (DNLI) rose 3.14% after hours to $18.40, following a regular-session decline of 1.76% to $17.84. The company did not release news on Tuesday, but the modest rebound suggests investor interest remains steady in the neurodegenerative disease-focused biotech.
TScan Therapeutics, Inc. (TCRX) added 3.97% after hours to $0.99, recovering from a 6.65% drop at the close to $0.95. The company last reported Q3 results on November 12, noting revenue growth to $2.5 million from $1.0 million a year earlier, driven by its collaboration with Amgen. Net losses widened to $35.7 million, reflecting higher R&D expenses.
Nyxoah SA (NYXH) climbed 4.03% after hours to $4.90, following a 4.66% decline at the close to $4.71. The company recently disclosed transparency notifications showing Robert Taub and BMI Estate increased their voting rights to 10.14% of the company's total, up from 9.97% in late November. The filings highlight growing insider ownership.
Dyne Therapeutics, Inc. (DYN) rose 4.80% after hours to $20.95, rebounding from a 3.01% decline at the close to $19.99. The company last reported Q3 results on November 5, with net losses widening to $108.0 million compared to $97.1 million a year earlier, as it continues to advance its pipeline of muscle disease therapies.
Outlook Therapeutics, Inc. (OTLK) gained 3.83% after hours to $1.90, after closing down 1.61% at $1.83. No new corporate updates were released on Tuesday, but the stock's rebound reflects investor positioning ahead of regulatory milestones for its ophthalmic drug candidate.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.